Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer

Recruitment Status
RECRUITING
(See Contacts and Locations)Verified March 2026 by ECOG-ACRIN Cancer Research Group
Sponsor
ECOG-ACRIN Cancer Research Group
Information Provided by (Responsible Party)
ECOG-ACRIN Cancer Research Group
Clinicaltrials.gov Identifier
NCT06475989
Other Study ID Numbers:
EA3231
First Submitted
May 16, 2024
First Posted
June 25, 2024
Last Update Posted
May 14, 2026
Last Verified
March 2026

ClinicalTrials.gov processed this data on May 2026. Link to the current ClinicalTrials.gov record .

History of Changes

Study Details

Study Description

PRIMARY OBJECTIVE:

I. To compare progression-free survival (PFS) in patients with BRAF V600Em differentiated thyroid cancer who progressed on frontline multikinase inhibitor treated with dabrafenib/trametinib or cabozantinib.

SECONDARY OBJECTIVES:

I. To compare the objective response rate in patients with BRAF V600Em differentiated thyroid cancer that progressed on frontline multikinase inhibitor treated with dabrafenib/trametinib or cabozantinib.

II. To compare the duration of response in patients with BRAF V600Em differentiated thyroid cancer that progressed on frontline multikinase inhibitor treated with dabrafenib/trametinib or cabozantinib.

III. To compare the overall survival in patients with BRAF V600Em differentiated thyroid cancer that progressed on frontline multikinase inhibitor treated with dabrafenib/trametinib or cabozantinib.

IV. To compare the PFS2 in patients with BRAF V600Em differentiated thyroid cancer that progressed on frontline multikinase inhibitor treated with dabrafenib/trametinib or cabozantinib.

V. To compare the safety/tolerability in patients with BRAF V600Em differentiated thyroid cancer that progressed on frontline multikinase inhibitor treated with dabrafenib/trametinib or cabozantinib.

QUALITY OF LIFE OBJECTIVE:

I. To assess patient tolerability of treatment using the Functional Assessment Cancer Therapy General (FACT G)P5 and general quality of life using the FACT-G7.

OUTLINE: Patients are randomized to 1 of 2 arms. Patients may crossover to other treatment arm at the time of progression.

ARM A: Patients receive dabrafenib orally (PO) twice per day (BID) and trametinib PO once per day (QD) on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo computed tomography (CT) scan, blood sample collection and may undergo magnetic resonance imaging (MRI) throughout the study.

ARM B: Patients receive cabozantinib PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan, blood sample collection and may undergo MRI throughout the study.

After completion of study treatment, patients are followed up every 3 months for 2 years and then every 6 months thereafter up to 5 years.

Condition or DiseaseIntervention/Treatment
Refractory Differentiated Thyroid Gland Carcinoma
Procedure: Biospecimen CollectionProcedure: Biospecimen Collection

Study Design

Study TypeInterventional
Actual Enrollment264 participants
Design AllocationRandomized
Interventional ModelParallel Assignment
MaskingNone (Open Label)
Primary PurposeTreatment
Official TitleA Randomized Phase III Study of BRAF-Targeted Therapy vs Cabozantinib in RAI-Refractory Differentiated Thyroid Cancer With BRAF V600Em
Study Start DateAugust 21, 2024
Actual Primary Completion Date4yrs 4mos from now
Actual Study Completion Date4yrs 4mos from now

Groups and Cohorts

Group/CohortIntervention/Treatment
Arm A (Dabrafenib and trametinib)
Patients receive dabrafenib PO BID and trametinib PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan, blood sample collection and may undergo MRI throughout the study.
Procedure: Biospecimen Collection
Undergo blood sample collection
Arm B (Cabozantinib)
Patients receive cabozantinib PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan, blood sample collection and may undergo MRI throughout the study.
Procedure: Biospecimen Collection
Undergo blood sample collection

Outcome Measures

Primary Outcome Measures
  1. Progression free survival (PFS)
    PFS will be compared between the two groups using a stratified log-rank test with one-sided type I error of 0.05. Median PFS and 95% confidence interval (CI) for each treatment arm will be estimated using the Kaplan-Meier method. The stratified hazard ratio and 95% CI will be estimated using a Cox proportional hazard model with treatment group as the independent variable.
Secondary Outcome Measures
  1. Objective response
    Will be assessed based on international criteria proposed by the RECIST 1.1 guideline. Response (complete and partial responses) rate will be estimated. Will be compared using the Fisher's exact test.
  2. Overall survival
    Median and 95% CI will be estimated in each arm using the Kaplan-Meier method.
  3. Duration of response
    Median and 95% CI will be estimated in each arm using the Kaplan-Meier method.
  4. PFS2 - the time from randomization to progression on subsequent therapy or death from any cause (whichever occurs first)
    Median and 95% CI will be estimated in each arm using the Kaplan-Meier method. PFS2 will be measured for every patient. For patients who receive a next line of therapy, PFS2 will be measured from the time of randomization to radiographic progression on the next line of therapy after the protocol-assigned therapy, or death from any cause, whichever occurs first. If patients are alive and have not had progression on the next of line therapy, they will be censored at the last assessment on the next line of therapy, and PFS2 will be measured from the time of randomization to the last assessment. For patients who do not receive the next line of therapy, PFS2 will be measured from the time of randomization to last assessed on the protocol-assigned therapy and will be censored unless death occurs, in which case death will count as an event.
  5. Incidence of adverse events
    Using the National Cancer Institute's Common Terminology Criteria for Adverse Events. Response rate and grade 3 or higher toxicity rates will be compared using the Fisher's exact test between the two arms.

Eligibility Criteria

Ages Eligible for Study(Adult, Older Adult)
Sexes Eligible for StudyAll
Accepts Healthy VolunteersNo
Inclusion Criteria
Patient must be ≥ 18 years of age
Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status 0-2
Patient must have differentiated thyroid cancer (DTC) with BRAF V600E mutation as determined by local testing, including the following subtypes (Note: results of a previous biopsy will be accepted):
Papillary thyroid carcinoma including histological variants of papillary thyroid carcinoma (PTC) such as follicular variant, tall cell, columnar cell, cribriform-morular, solid, oxyphil, Warthin-like, trabecular, tumor with nodular fasciitis-like stroma, Hürthle cell variant of papillary carcinoma, poorly differentiated.
Follicular thyroid carcinoma including histological variants of follicular thyroid carcinoma (FTC) such as Hürthle cell, clear cell, insular, and poorly differentiated
Patient must have been previously treated with or deemed ineligible for treatment with Iodine-131 for DTC, and must be receiving thyroxine suppression therapy
Patient must have had prior treatment with at least one of the following vascular endothelial growth factor receptors (VEGFR)-targeting tyrosine kinase inhibitor (TKI) agents for DTC: lenvatinib or sorafenib.
NOTE: Up to two prior VEGFR-targeting TKI agents are allowed including, but not limited to lenvatinib and sorafenib
Patient must have measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) 1·1 on chest CT (computed tomography)/abdominal/pelvis CT/MRI (magnetic resonance imaging) performed within 4 weeks prior to randomization
Patient must have radiographic progression by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 over any time interval on or after most recent prior systemic treatment
Patient must not have any of the following cardiovascular and thromboembolic disorders or medical conditions:
Congestive heart failure class 3 or 4 as defined by the New York Heart Association, unstable angina pectoris, or serious cardiac arrhythmias.
Uncontrolled hypertension defined as sustained blood pressure \> 150 mm Hg systolic or \> 100 mm Hg diastolic despite optimal antihypertensive treatment.
Stroke, myocardial infarction, or thromboembolic event (e.g., deep venous thrombosis, pulmonary embolism) within 6 months prior to randomization. Patients with more recent diagnosis of deep venous thrombosis are allowed if stable and treated with therapeutic anticoagulation for at least 6 weeks prior to randomization
Patient must not have any clinically significant hematemesis or haemoptysis of \> 0·5 teaspoon (\> 2·5 mL) of red blood or history of other significant bleeding within 3 months prior to randomization
Patient must not have any cavitating pulmonary lesion(s) or lesions invading major pulmonary blood vessels
Patient must not be on any concomitant anticoagulation with oral anticoagulants or platelet inhibitors, except for the following allowed agents:
Low-dose aspirin for cardioprotection.
Therapeutic anticoagulation with any agent in patients (1) without known brain metastases, (2) on a stable dose for at least 6 weeks prior to randomization, and (3) with no clinically significant hemorrhagic complications from the anticoagulation regimen or the tumor
Patient must not have any gastrointestinal (GI) disorders associated with a high risk of perforation or fistula formation:
Tumors invading the GI tract, active peptic ulcer disease, inflammatory bowel disease, ulcerative colitis, diverticulitis, cholecystitis, symptomatic cholangitis or appendicitis, acute pancreatitis, or acute obstruction of the pancreatic or biliary duct, or gastric outlet obstruction
Abdominal fistula, GI perforation, bowel obstruction, or intra-abdominal abscess within 6 months prior to randomization
Patient must have completed any prior local therapy (e.g., surgery, radiation, ablation) at least 4 weeks prior to randomization, with complete wound healing and resolution of clinically relevant complications from prior local therapy
Patient must not have had major surgery (e.g., GI surgery, removal or biopsy of brain metastasis) within 8 weeks prior to randomization. Complete wound healing from major surgery must have occurred 4 weeks prior to randomization and from minor surgery (e.g., simple excision, tooth extraction) at least 10 days prior to randomization
Patient must not have any lesion(s) with ≥ 2cm growth within 3 months or ≥ 1.5cm growth within 2 months prior to randomization, and must not have documented anaplastic histology at or following cancer recurrence
Patient must not have had prior treatment with cabozantinib or any prior BRAF targeted therapy for thyroid cancer
Patient must not be pregnant or breast-feeding due to the potential harm to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used. All patients of childbearing potential must have a blood test or urine study within 14 days prior to randomization to rule out pregnancy. A patient of childbearing potential is defined as anyone, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy; or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months).
Patients must not expect to conceive or father children by using accepted and effective method(s) of contraception or by abstaining from sexual intercourse for the duration of their participation in the study and for 2 weeks after the last dose of dabrafenib and 4 months after the last dose of trametinib or cabozantinib. Patients must also not breastfeed while on study treatment and for 2 weeks after the last dose of dabrafenib and for 4 months after the last dose of trametinib or cabozantinib.
NOTE: Patients of childbearing potential who are on hormonal contraceptives may be at risks because dabrafenib may decrease the efficacy of hormonal contraceptives. An effective non-hormonal contraception should be used during therapy and for 2 weeks following discontinuation of dabrafenib and at least 4 months following the last dose of trametinib and cabozantinib
Patient must have the ability to understand and the willingness to sign a written informed consent document. Patients with impaired decision-making capacity (IDMC) who have a legally authorized representative (LAR) or caregiver and/or family member available will also be considered eligible
Hemoglobulin (Hgb) ≥ 8 g/dL obtained ≤ 28 days prior to protocol randomization
Leukocytes ≥ 3,000/mcL obtained ≤ 28 days prior to protocol randomization
Absolute neutrophil count (ANC) ≥ 1,500/mcL obtained ≤ 28 days prior to protocol randomization
Platelets ≥ 100,000/mcL obtained ≤ 28 days prior to protocol randomization
Total bilirubin ≤ 2.0 x institutional upper limit of normal (ULN) obtained ≤ 28 days prior to protocol randomization
Aspartate aminotransferase (AST)(serum glutamic oxaloacetic transaminase \[SGOT\])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase \[SGPT\]) ≤ 3.0 × institutional ULN or \< 5.0 x ULN with the presence of hepatic metastasis obtained ≤ 28 days prior to protocol randomization
Estimated glomerular filtration rate (eGFR) ≥ 30 mL/min/1.73 m² obtained ≤ 28 days prior to protocol randomization
Urine protein/creatinine (UPC) ratio ≥ 1 obtained ≤ 28 days prior to protocol randomization
Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of randomization are eligible for this trial
For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
Patients with treated brain metastases are eligible if follow-up brain imaging obtained after central nervous system (CNS)-directed therapy (radiotherapy and/or surgery) shows no evidence of progression. CNS disease must be stable for at least 4 weeks prior to randomization; patients must be neurologically asymptomatic and without corticosteroid treatment at time of randomization
Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
Patients must have corrected QT interval calculated by the Fridericia formula (QTcF) ≤ 500 ms obtained within 28 days prior to randomization.
NOTE: If a single electrocardiogram (ECG) shows a QTcF with an absolute value \> 500 ms, two additional ECGs at intervals of approximately 3 minutes (min) must be performed within 30 min after the initial ECG, and the average of these 3 consecutive results for QTcF will be used to determine eligibility
Patient must be English or Spanish speaking to be eligible for the quality of life (QOL) component of the study.
NOTE: Sites cannot translate the associated QOL forms
Exclusion Criteria
Inclusion Criteria:
Patient must be ≥ 18 years of age
Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status 0-2
Patient must have differentiated thyroid cancer (DTC) with BRAF V600E mutation as determined by local testing, including the following subtypes (Note: results of a previous biopsy will be accepted):
Papillary thyroid carcinoma including histological variants of papillary thyroid carcinoma (PTC) such as follicular variant, tall cell, columnar cell, cribriform-morular, solid, oxyphil, Warthin-like, trabecular, tumor with nodular fasciitis-like stroma, Hürthle cell variant of papillary carcinoma, poorly differentiated.
Follicular thyroid carcinoma including histological variants of follicular thyroid carcinoma (FTC) such as Hürthle cell, clear cell, insular, and poorly differentiated
Patient must have been previously treated with or deemed ineligible for treatment with Iodine-131 for DTC, and must be receiving thyroxine suppression therapy
Patient must have had prior treatment with at least one of the following vascular endothelial growth factor receptors (VEGFR)-targeting tyrosine kinase inhibitor (TKI) agents for DTC: lenvatinib or sorafenib.
NOTE: Up to two prior VEGFR-targeting TKI agents are allowed including, but not limited to lenvatinib and sorafenib
Patient must have measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) 1·1 on chest CT (computed tomography)/abdominal/pelvis CT/MRI (magnetic resonance imaging) performed within 4 weeks prior to randomization
Patient must have radiographic progression by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 over any time interval on or after most recent prior systemic treatment
Patient must not have any of the following cardiovascular and thromboembolic disorders or medical conditions:
Congestive heart failure class 3 or 4 as defined by the New York Heart Association, unstable angina pectoris, or serious cardiac arrhythmias.
Uncontrolled hypertension defined as sustained blood pressure \> 150 mm Hg systolic or \> 100 mm Hg diastolic despite optimal antihypertensive treatment.
Stroke, myocardial infarction, or thromboembolic event (e.g., deep venous thrombosis, pulmonary embolism) within 6 months prior to randomization. Patients with more recent diagnosis of deep venous thrombosis are allowed if stable and treated with therapeutic anticoagulation for at least 6 weeks prior to randomization
Patient must not have any clinically significant hematemesis or haemoptysis of \> 0·5 teaspoon (\> 2·5 mL) of red blood or history of other significant bleeding within 3 months prior to randomization
Patient must not have any cavitating pulmonary lesion(s) or lesions invading major pulmonary blood vessels
Patient must not be on any concomitant anticoagulation with oral anticoagulants or platelet inhibitors, except for the following allowed agents:
Low-dose aspirin for cardioprotection.
Therapeutic anticoagulation with any agent in patients (1) without known brain metastases, (2) on a stable dose for at least 6 weeks prior to randomization, and (3) with no clinically significant hemorrhagic complications from the anticoagulation regimen or the tumor
Patient must not have any gastrointestinal (GI) disorders associated with a high risk of perforation or fistula formation:
Tumors invading the GI tract, active peptic ulcer disease, inflammatory bowel disease, ulcerative colitis, diverticulitis, cholecystitis, symptomatic cholangitis or appendicitis, acute pancreatitis, or acute obstruction of the pancreatic or biliary duct, or gastric outlet obstruction
Abdominal fistula, GI perforation, bowel obstruction, or intra-abdominal abscess within 6 months prior to randomization
Patient must have completed any prior local therapy (e.g., surgery, radiation, ablation) at least 4 weeks prior to randomization, with complete wound healing and resolution of clinically relevant complications from prior local therapy
Patient must not have had major surgery (e.g., GI surgery, removal or biopsy of brain metastasis) within 8 weeks prior to randomization. Complete wound healing from major surgery must have occurred 4 weeks prior to randomization and from minor surgery (e.g., simple excision, tooth extraction) at least 10 days prior to randomization
Patient must not have any lesion(s) with ≥ 2cm growth within 3 months or ≥ 1.5cm growth within 2 months prior to randomization, and must not have documented anaplastic histology at or following cancer recurrence
Patient must not have had prior treatment with cabozantinib or any prior BRAF targeted therapy for thyroid cancer
Patient must not be pregnant or breast-feeding due to the potential harm to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used. All patients of childbearing potential must have a blood test or urine study within 14 days prior to randomization to rule out pregnancy. A patient of childbearing potential is defined as anyone, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy; or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months).
Patients must not expect to conceive or father children by using accepted and effective method(s) of contraception or by abstaining from sexual intercourse for the duration of their participation in the study and for 2 weeks after the last dose of dabrafenib and 4 months after the last dose of trametinib or cabozantinib. Patients must also not breastfeed while on study treatment and for 2 weeks after the last dose of dabrafenib and for 4 months after the last dose of trametinib or cabozantinib.
NOTE: Patients of childbearing potential who are on hormonal contraceptives may be at risks because dabrafenib may decrease the efficacy of hormonal contraceptives. An effective non-hormonal contraception should be used during therapy and for 2 weeks following discontinuation of dabrafenib and at least 4 months following the last dose of trametinib and cabozantinib
Patient must have the ability to understand and the willingness to sign a written informed consent document. Patients with impaired decision-making capacity (IDMC) who have a legally authorized representative (LAR) or caregiver and/or family member available will also be considered eligible
Hemoglobulin (Hgb) ≥ 8 g/dL obtained ≤ 28 days prior to protocol randomization
Leukocytes ≥ 3,000/mcL obtained ≤ 28 days prior to protocol randomization
Absolute neutrophil count (ANC) ≥ 1,500/mcL obtained ≤ 28 days prior to protocol randomization
Platelets ≥ 100,000/mcL obtained ≤ 28 days prior to protocol randomization
Total bilirubin ≤ 2.0 x institutional upper limit of normal (ULN) obtained ≤ 28 days prior to protocol randomization
Aspartate aminotransferase (AST)(serum glutamic oxaloacetic transaminase \[SGOT\])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase \[SGPT\]) ≤ 3.0 × institutional ULN or \< 5.0 x ULN with the presence of hepatic metastasis obtained ≤ 28 days prior to protocol randomization
Estimated glomerular filtration rate (eGFR) ≥ 30 mL/min/1.73 m² obtained ≤ 28 days prior to protocol randomization
Urine protein/creatinine (UPC) ratio ≥ 1 obtained ≤ 28 days prior to protocol randomization
Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of randomization are eligible for this trial
For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
Patients with treated brain metastases are eligible if follow-up brain imaging obtained after central nervous system (CNS)-directed therapy (radiotherapy and/or surgery) shows no evidence of progression. CNS disease must be stable for at least 4 weeks prior to randomization; patients must be neurologically asymptomatic and without corticosteroid treatment at time of randomization
Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
Patients must have corrected QT interval calculated by the Fridericia formula (QTcF) ≤ 500 ms obtained within 28 days prior to randomization.
NOTE: If a single electrocardiogram (ECG) shows a QTcF with an absolute value \> 500 ms, two additional ECGs at intervals of approximately 3 minutes (min) must be performed within 30 min after the initial ECG, and the average of these 3 consecutive results for QTcF will be used to determine eligibility
Patient must be English or Spanish speaking to be eligible for the quality of life (QOL) component of the study.
NOTE: Sites cannot translate the associated QOL forms

Contacts and Locations

Sponsors and CollaboratorsECOG-ACRIN Cancer Research Group
Locations
Anchorage Associates in Radiation Medicine | Anchorage Alaska, United States, 98508Anchorage Radiation Therapy Center | Anchorage Alaska, United States, 99504Alaska Breast Care and Surgery LLC | Anchorage Alaska, United States, 99508Alaska Oncology and Hematology LLC | Anchorage Alaska, United States, 99508Alaska Women's Cancer Care | Anchorage Alaska, United States, 99508Katmai Oncology Group | Anchorage Alaska, United States, 99508Providence Alaska Medical Center | Anchorage Alaska, United States, 99508Mercy Hospital Fort Smith | Fort Smith Arkansas, United States, 72903CARTI Cancer Center | Little Rock Arkansas, United States, 72205Providence Saint Joseph Medical Center/Disney Family Cancer Center | Burbank California, United States, 91505UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care | Irvine California, United States, 92612Providence Queen of The Valley | Napa California, United States, 94558UC Irvine Health/Chao Family Comprehensive Cancer Center | Orange California, United States, 92868Stanford Cancer Institute Palo Alto | Palo Alto California, United States, 94304Providence Medical Foundation - Santa Rosa | Santa Rosa California, United States, 95403Providence Santa Rosa Memorial Hospital | Santa Rosa California, United States, 95405UCHealth University of Colorado Hospital | Aurora Colorado, United States, 80045UCHealth Highlands Ranch Hospital | Highlands Ranch Colorado, United States, 80129Smilow Cancer Hospital-Derby Care Center | Derby Connecticut, United States, 06418Smilow Cancer Hospital Care Center-Fairfield | Fairfield Connecticut, United States, 06824Smilow Cancer Hospital Care Center at Glastonbury | Glastonbury Connecticut, United States, 06033Smilow Cancer Hospital Care Center at Greenwich | Greenwich Connecticut, United States, 06830Smilow Cancer Hospital Care Center - Guilford | Guilford Connecticut, United States, 06437Smilow Cancer Hospital Care Center at Saint Francis | Hartford Connecticut, United States, 06105Smilow Cancer Center/Yale-New Haven Hospital | New Haven Connecticut, United States, 06510Yale University | New Haven Connecticut, United States, 06520Yale-New Haven Hospital North Haven Medical Center | North Haven Connecticut, United States, 06473Smilow Cancer Hospital Care Center at Long Ridge | Stamford Connecticut, United States, 06902Smilow Cancer Hospital-Torrington Care Center | Torrington Connecticut, United States, 06790Smilow Cancer Hospital Care Center-Trumbull | Trumbull Connecticut, United States, 06611Smilow Cancer Hospital-Waterbury Care Center | Waterbury Connecticut, United States, 06708Smilow Cancer Hospital Care Center - Waterford | Waterford Connecticut, United States, 06385Holy Cross Hospital | Fort Lauderdale Florida, United States, 33308Mayo Clinic in Florida | Jacksonville Florida, United States, 32224-9980Emory University Hospital Midtown | Atlanta Georgia, United States, 30308Saint Alphonsus Cancer Care Center-Boise | Boise Idaho, United States, 83706Saint Luke's Cancer Institute - Boise | Boise Idaho, United States, 83712Saint Alphonsus Cancer Care Center-Caldwell | Caldwell Idaho, United States, 83605Kootenai Health - Coeur d'Alene | Coeur d'Alene Idaho, United States, 83814Walter Knox Memorial Hospital | Emmett Idaho, United States, 83617Saint Luke's Cancer Institute - Fruitland | Fruitland Idaho, United States, 83619Idaho Urologic Institute-Meridian | Meridian Idaho, United States, 83642Saint Luke's Cancer Institute - Meridian | Meridian Idaho, United States, 83642Saint Alphonsus Cancer Care Center-Nampa | Nampa Idaho, United States, 83687Saint Luke's Cancer Institute - Nampa | Nampa Idaho, United States, 83687Kootenai Clinic Cancer Services - Post Falls | Post Falls Idaho, United States, 83854Kootenai Clinic Cancer Services - Sandpoint | Sandpoint Idaho, United States, 83864Saint Luke's Cancer Institute - Twin Falls | Twin Falls Idaho, United States, 83301OSF Saint Anthony's Health Center | Alton Illinois, United States, 62002Advocate Outpatient Center - Aurora | Aurora Illinois, United States, 60506Advocate Good Shepherd Hospital | Barrington Illinois, United States, 60010Saint Mary's Hospital | Centralia Illinois, United States, 62801Northwestern University | Chicago Illinois, United States, 60611University of Illinois | Chicago Illinois, United States, 60612University of Chicago Comprehensive Cancer Center | Chicago Illinois, United States, 60637Advocate Illinois Masonic Medical Center | Chicago Illinois, United States, 60657AMG Crystal Lake - Oncology | Crystal Lake Illinois, United States, 60014Northwestern Medicine Cancer Center Kishwaukee | DeKalb Illinois, United States, 60115Advocate Good Samaritan Hospital | Downers Grove Illinois, United States, 60515Advocate Sherman Hospital | Elgin Illinois, United States, 60123Northwestern Medicine Cancer Center Delnor | Geneva Illinois, United States, 60134Northwestern Medicine Glenview Outpatient Center | Glenview Illinois, United States, 60026Northwestern Medicine Grayslake Outpatient Center | Grayslake Illinois, United States, 60030Advocate South Suburban Hospital | Hazel Crest Illinois, United States, 60429Northwestern Medicine Lake Forest Hospital | Lake Forest Illinois, United States, 60045AMG Libertyville - Oncology | Libertyville Illinois, United States, 60048Condell Memorial Hospital | Libertyville Illinois, United States, 60048SSM Health Good Samaritan | Mount Vernon Illinois, United States, 62864UC Comprehensive Cancer Center at Silver Cross | New Lenox Illinois, United States, 60451Advocate Christ Medical Center | Oak Lawn Illinois, United States, 60453-2699Advocate Outpatient Center - Oak Lawn | Oak Lawn Illinois, United States, 60453Northwestern Medicine Orland Park | Orland Park Illinois, United States, 60462University of Chicago Medicine-Orland Park | Orland Park Illinois, United States, 60462Advocate High Tech Medical Park | Palos Heights Illinois, United States, 60463Advocate Lutheran General Hospital | Park Ridge Illinois, United States, 60068Memorial Hospital East | Shiloh Illinois, United States, 62269Northwestern Medicine Cancer Center Warrenville | Warrenville Illinois, United States, 60555UChicago Medicine Northwest Indiana | Crown Point Indiana, United States, 46307UI Health Care Mission Cancer and Blood - Ankeny Clinic | Ankeny Iowa, United States, 50023University of Iowa Healthcare Cancer Services Quad Cities | Bettendorf Iowa, United States, 52722Saint Anthony Regional Hospital | Carroll Iowa, United States, 51401Mercy Hospital | Cedar Rapids Iowa, United States, 52403Oncology Associates at Mercy Medical Center | Cedar Rapids Iowa, United States, 52403Mercy Cancer Center-West Lakes | Clive Iowa, United States, 50325UI Health Care Mission Cancer and Blood - West Des Moines Clinic | Clive Iowa, United States, 50325Heartland Oncology and Hematology LLP | Council Bluffs Iowa, United States, 51503Methodist Jennie Edmundson Hospital | Council Bluffs Iowa, United States, 51503Nebraska Cancer Specialists/Oncology Hematology West PC - MEJ | Council Bluffs Iowa, United States, 51503Greater Regional Medical Center | Creston Iowa, United States, 50801Iowa Methodist Medical Center | Des Moines Iowa, United States, 50309UI Health Care Mission Cancer and Blood - Des Moines Clinic | Des Moines Iowa, United States, 50309Broadlawns Medical Center | Des Moines Iowa, United States, 50314Mercy Medical Center - Des Moines | Des Moines Iowa, United States, 50314UI Health Care Mission Cancer and Blood - Laurel Clinic | Des Moines Iowa, United States, 50314UI Healthcare Mission Cancer and Blood - Fort Dodge | Fort Dodge Iowa, United States, 50501University of Iowa/Holden Comprehensive Cancer Center | Iowa City Iowa, United States, 52242UI Healthcare Mission Cancer and Blood - Pella | Pella Iowa, United States, 50219UI Health Care Mission Cancer and Blood - Waukee Clinic | Waukee Iowa, United States, 50263Mercy Medical Center-West Lakes | West Des Moines Iowa, United States, 50266The Iowa Clinic PC | West Des Moines Iowa, United States, 50266Central Care Cancer Center - Garden City | Garden City Kansas, United States, 67846Central Care Cancer Center - Great Bend | Great Bend Kansas, United States, 67530Mercy Hospital Pittsburg | Pittsburg Kansas, United States, 66762University of Kentucky/Markey Cancer Center | Lexington Kentucky, United States, 40536University of Maryland/Greenebaum Cancer Center | Baltimore Maryland, United States, 21201MyMichigan Medical Center Gratiot | Alma Michigan, United States, 48801MyMichigan Medical Center Alpena | Alpena Michigan, United States, 49707Trinity Health IHA - Obstetrics and Gynecology West Arbor | Ann Arbor Michigan, United States, 48103Trinity Health Saint Joseph Mercy Hospital Ann Arbor | Ann Arbor Michigan, United States, 48106University of Michigan Rogel Cancer Center | Ann Arbor Michigan, United States, 48109Trinity Health IHA Medical Group Hematology Oncology - Brighton | Brighton Michigan, United States, 48114Trinity Health Medical Center - Brighton | Brighton Michigan, United States, 48114University of Michigan - Brighton Center for Specialty Care | Brighton Michigan, United States, 48116Trinity Health IHA Medical Group Hematology Oncology - Canton | Canton Michigan, United States, 48188Trinity Health Medical Center - Canton | Canton Michigan, United States, 48188Caro Cancer Center | Caro Michigan, United States, 48723Chelsea Hospital | Chelsea Michigan, United States, 48118Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital | Chelsea Michigan, United States, 48118Hematology Oncology Consultants-Clarkston | Clarkston Michigan, United States, 48346Newland Medical Associates-Clarkston | Clarkston Michigan, United States, 48346Henry Ford Health Saint John Hospital | Detroit Michigan, United States, 48236Henry Ford River District Hospital | East China Township Michigan, United States, 48054Cancer Hematology Centers - Flint | Flint Michigan, United States, 48503Genesee Hematology Oncology PC | Flint Michigan, United States, 48503Genesys Hurley Cancer Institute | Flint Michigan, United States, 48503Hurley Medical Center | Flint Michigan, United States, 48503MyMichigan Medical Center Gladwin | Gladwin Michigan, United States, 48624Henry Ford Saint John Hospital - Academic | Grosse Pointe Woods Michigan, United States, 48236Henry Ford Saint John Hospital - Breast | Grosse Pointe Woods Michigan, United States, 48236Henry Ford Saint John Hospital - Van Elslander | Grosse Pointe Woods Michigan, United States, 48236University of Michigan Health - Sparrow Lansing | Lansing Michigan, United States, 48912Trinity Health Saint Mary Mercy Livonia Hospital | Livonia Michigan, United States, 48154Henry Ford Saint John Hospital - Macomb Medical | Macomb Michigan, United States, 48044Henry Ford Warren Hospital - Breast Macomb | Macomb Michigan, United States, 48044Saint Mary's Oncology/Hematology Associates of Marlette | Marlette Michigan, United States, 48453MyMichigan Medical Center Midland | Midland Michigan, United States, 48670MyMichigan Medical Center Mount Pleasant | Mount Pleasant Michigan, United States, 48858Hope Cancer Center | Pontiac Michigan, United States, 48341Michigan Healthcare Professionals Pontiac | Pontiac Michigan, United States, 48341Newland Medical Associates-Pontiac | Pontiac Michigan, United States, 48341Trinity Health Saint Joseph Mercy Oakland Hospital | Pontiac Michigan, United States, 48341MyMichigan Medical Center Saginaw | Saginaw Michigan, United States, 48601Oncology Hematology Associates of Saginaw Valley PC | Saginaw Michigan, United States, 48604MyMichigan Medical Center Tawas | Tawas City Michigan, United States, 48764Henry Ford Health Warren Hospital | Warren Michigan, United States, 48093Henry Ford Madison Heights Hospital - Breast | Warren Michigan, United States, 48093Henry Ford Warren Hospital - GLCMS | Warren Michigan, United States, 48093Saint Mary's Oncology/Hematology Associates of West Branch | West Branch Michigan, United States, 48661Huron Gastroenterology PC | Ypsilanti Michigan, United States, 48106Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus | Ypsilanti Michigan, United States, 48197Sanford Joe Lueken Cancer Center | Bemidji Minnesota, United States, 56601Minnesota Oncology - Burnsville | Burnsville Minnesota, United States, 55337Cambridge Medical Center | Cambridge Minnesota, United States, 55008Minnesota Oncology Hematology PA-Chaska | Chaska Minnesota, United States, 55318Mercy Hospital | Coon Rapids Minnesota, United States, 55433Minnesota Oncology - Coon Rapids | Coon Rapids Minnesota, United States, 55433Fairview Southdale Hospital | Edina Minnesota, United States, 55435Minnesota Oncology - Edina | Edina Minnesota, United States, 55435Fairview Clinics and Surgery Center Maple Grove | Maple Grove Minnesota, United States, 55369Minnesota Oncology - Maple Grove | Maple Grove Minnesota, United States, 55369Minnesota Oncology Hematology PA-Maplewood | Maplewood Minnesota, United States, 55109Saint John's Hospital - Healtheast | Maplewood Minnesota, United States, 55109Abbott-Northwestern Hospital | Minneapolis Minnesota, United States, 55407Hennepin County Medical Center | Minneapolis Minnesota, United States, 55415Health Partners Inc | Minneapolis Minnesota, United States, 55454Monticello Cancer Center | Monticello Minnesota, United States, 55362New Ulm Medical Center | New Ulm Minnesota, United States, 56073Fairview Northland Medical Center | Princeton Minnesota, United States, 55371North Memorial Medical Health Center | Robbinsdale Minnesota, United States, 55422Mayo Clinic in Rochester | Rochester Minnesota, United States, 55905Park Nicollet Clinic - Saint Louis Park | Saint Louis Park Minnesota, United States, 55416Regions Hospital | Saint Paul Minnesota, United States, 55101United Hospital | Saint Paul Minnesota, United States, 55102Saint Francis Regional Medical Center | Shakopee Minnesota, United States, 55379Lakeview Hospital | Stillwater Minnesota, United States, 55082Sanford Thief River Falls Medical Center | Thief River Falls Minnesota, United States, 56701Ridgeview Medical Center | Waconia Minnesota, United States, 55387Rice Memorial Hospital | Willmar Minnesota, United States, 56201Minnesota Oncology Hematology PA-Woodbury | Woodbury Minnesota, United States, 55125Sanford Cancer Center Worthington | Worthington Minnesota, United States, 56187Fairview Lakes Medical Center | Wyoming Minnesota, United States, 55092Mercy Oncology and Hematology - Clayton-Clarkson | Ballwin Missouri, United States, 63011Central Care Cancer Center - Bolivar | Bolivar Missouri, United States, 65613Cox Cancer Center Branson | Branson Missouri, United States, 65616Mercy Cancer Center - Cape Girardeau | Cape Girardeau Missouri, United States, 63703Siteman Cancer Center at Saint Peters Hospital | City of Saint Peters Missouri, United States, 63376Siteman Cancer Center at West County Hospital | Creve Coeur Missouri, United States, 63141Freeman Health System | Joplin Missouri, United States, 64804Mercy Hospital Joplin | Joplin Missouri, United States, 64804Lake Regional Hospital | Osage Beach Missouri, United States, 65065Mercy Clinic-Rolla-Cancer and Hematology | Rolla Missouri, United States, 65401Phelps Health Delbert Day Cancer Institute | Rolla Missouri, United States, 65401Heartland Regional Medical Center | Saint Joseph Missouri, United States, 64506Mercy Hospital Springfield | Springfield Missouri, United States, 65804CoxHealth South Hospital | Springfield Missouri, United States, 65807Mercy Infusion Center - Chippewa | St Louis Missouri, United States, 63109Washington University School of Medicine | St Louis Missouri, United States, 63110Mercy Hospital South | St Louis Missouri, United States, 63128Siteman Cancer Center-South County | St Louis Missouri, United States, 63129Siteman Cancer Center at Christian Hospital | St Louis Missouri, United States, 63136Mercy Hospital Saint Louis | St Louis Missouri, United States, 63141Mercy Hospital Washington | Washington Missouri, United States, 63090Community Hospital of Anaconda | Anaconda Montana, United States, 59711Billings Clinic Cancer Center | Billings Montana, United States, 59101Bozeman Health Deaconess Hospital | Bozeman Montana, United States, 59715Benefis Sletten Cancer Institute | Great Falls Montana, United States, 59405Great Falls Clinic | Great Falls Montana, United States, 59405Hi-Line Sletten Cancer Center | Havre Montana, United States, 59501Benefis Helena Specialty Center | Helena Montana, United States, 59601Logan Health Medical Center | Kalispell Montana, United States, 59901Saint Patrick Hospital - Community Hospital | Missoula Montana, United States, 59802Community Medical Center | Missoula Montana, United States, 59804Nebraska Cancer Specialists/Oncology Hematology West PC - MECC | Omaha Nebraska, United States, 68114Nebraska Methodist Hospital | Omaha Nebraska, United States, 68114Oncology Associates PC | Omaha Nebraska, United States, 68114Duke Cancer Center Cary | Cary North Carolina, United States, 27518UNC Lineberger Comprehensive Cancer Center | Chapel Hill North Carolina, United States, 27599Duke University Medical Center | Durham North Carolina, United States, 27710Duke Cancer Center Raleigh | Raleigh North Carolina, United States, 27609Sanford Bismarck Medical Center | Bismarck North Dakota, United States, 58501Sanford South University Medical Center | Fargo North Dakota, United States, 58103Southpointe-Sanford Medical Center Fargo | Fargo North Dakota, United States, 58103Sanford Medical Center Fargo | Fargo North Dakota, United States, 58104Sanford Broadway Medical Center | Fargo North Dakota, United States, 58122Sanford Roger Maris Cancer Center | Fargo North Dakota, United States, 58122Cancer Centers of Southwest Oklahoma Research | Lawton Oklahoma, United States, 73505University of Oklahoma Health Sciences Center | Oklahoma City Oklahoma, United States, 73104Mercy Hospital Oklahoma City | Oklahoma City Oklahoma, United States, 73120Saint Alphonsus Cancer Care Center-Baker City | Baker City Oregon, United States, 97814Saint Charles Health System | Bend Oregon, United States, 97701Clackamas Radiation Oncology Center | Clackamas Oregon, United States, 97015Providence Cancer Institute Clackamas Clinic | Clackamas Oregon, United States, 97015Bay Area Hospital | Coos Bay Oregon, United States, 97420Providence Hood River Memorial Hospital | Hood River Oregon, United States, 97031Providence Newberg Medical Center | Newberg Oregon, United States, 97132Saint Alphonsus Cancer Care Center-Ontario | Ontario Oregon, United States, 97914Providence Willamette Falls Medical Center | Oregon City Oregon, United States, 97045Providence Portland Medical Center | Portland Oregon, United States, 97213Providence Saint Vincent Medical Center | Portland Oregon, United States, 97225Oregon Health and Science University | Portland Oregon, United States, 97239Saint Charles Health System-Redmond | Redmond Oregon, United States, 97756Lehigh Valley Hospital-Cedar Crest | Allentown Pennsylvania, United States, 18103Lehigh Valley Hospital - Muhlenberg | Bethlehem Pennsylvania, United States, 18017Pocono Medical Center | East Stroudsburg Pennsylvania, United States, 18301UPMC Hillman Cancer Center Erie | Erie Pennsylvania, United States, 16505Lehigh Valley Hospital-Hazleton | Hazleton Pennsylvania, United States, 18201University of Pennsylvania/Abramson Cancer Center | Philadelphia Pennsylvania, United States, 19104University of Pittsburgh Cancer Institute (UPCI) | Pittsburgh Pennsylvania, United States, 15232Smilow Cancer Hospital Care Center - Westerly | Westerly Rhode Island, United States, 02891Medical University of South Carolina | Charleston South Carolina, United States, 29425Sanford Cancer Center Oncology Clinic | Sioux Falls South Dakota, United States, 57104Sanford USD Medical Center - Sioux Falls | Sioux Falls South Dakota, United States, 57117-5134Vanderbilt Breast Center at One Hundred Oaks | Nashville Tennessee, United States, 37204Vanderbilt University/Ingram Cancer Center | Nashville Tennessee, United States, 37232Huntsman Cancer Institute/University of Utah | Salt Lake City Utah, United States, 84112Providence Regional Cancer System-Aberdeen | Aberdeen Washington, United States, 98520PeaceHealth Saint Joseph Medical Center | Bellingham Washington, United States, 98225Providence Regional Cancer System-Centralia | Centralia Washington, United States, 98531Swedish Cancer Institute-Edmonds | Edmonds Washington, United States, 98026Providence Regional Cancer Partnership | Everett Washington, United States, 98201Swedish Cancer Institute-Issaquah | Issaquah Washington, United States, 98029Kadlec Clinic Hematology and Oncology | Kennewick Washington, United States, 99336Providence Regional Cancer System-Lacey | Lacey Washington, United States, 98503PeaceHealth Saint John Medical Center | Longview Washington, United States, 98632Skagit Regional Health Cancer Care Center | Mount Vernon Washington, United States, 98274Swedish Medical Center-Ballard Campus | Seattle Washington, United States, 98107Swedish Medical Center-Cherry Hill | Seattle Washington, United States, 98122-5711Swedish Medical Center-First Hill | Seattle Washington, United States, 98122PeaceHealth United General Medical Center | Sedro-Woolley Washington, United States, 98284Cancer Care Northwest - Spokane South | Spokane Washington, United States, 99202Cancer Care Northwest-Valley | Spokane Washington, United States, 99216Cancer Care Northwest-North Spokane | Spokane Washington, United States, 99218PeaceHealth Southwest Medical Center | Vancouver Washington, United States, 98664Providence Saint Mary Regional Cancer Center | Walla Walla Washington, United States, 99362Aurora Cancer Care-Southern Lakes VLCC | Burlington Wisconsin, United States, 53105Aurora Saint Luke's South Shore | Cudahy Wisconsin, United States, 53110Marshfield Medical Center-EC Cancer Center | Eau Claire Wisconsin, United States, 54701Aurora Health Care Germantown Health Center | Germantown Wisconsin, United States, 53022Aurora Cancer Care-Grafton | Grafton Wisconsin, United States, 53024Aurora BayCare Medical Center | Green Bay Wisconsin, United States, 54311Aurora Cancer Care-Kenosha South | Kenosha Wisconsin, United States, 53142Aurora Bay Area Medical Group-Marinette | Marinette Wisconsin, United States, 54143Marshfield Medical Center-Marshfield | Marshfield Wisconsin, United States, 54449Aurora Cancer Care-Milwaukee | Milwaukee Wisconsin, United States, 53209Aurora Saint Luke's Medical Center | Milwaukee Wisconsin, United States, 53215Aurora Sinai Medical Center | Milwaukee Wisconsin, United States, 53233Marshfield Medical Center - Minocqua | Minocqua Wisconsin, United States, 54548Cancer Center of Western Wisconsin | New Richmond Wisconsin, United States, 54017Vince Lombardi Cancer Clinic - Oshkosh | Oshkosh Wisconsin, United States, 54904Aurora Cancer Care-Racine | Racine Wisconsin, United States, 53406Marshfield Medical Center-Rice Lake | Rice Lake Wisconsin, United States, 54868Vince Lombardi Cancer Clinic-Sheboygan | Sheboygan Wisconsin, United States, 53081Marshfield Medical Center-River Region at Stevens Point | Stevens Point Wisconsin, United States, 54482Aurora Medical Center in Summit | Summit Wisconsin, United States, 53066Vince Lombardi Cancer Clinic-Two Rivers | Two Rivers Wisconsin, United States, 54241Aurora Cancer Care-Milwaukee West | Wauwatosa Wisconsin, United States, 53226Aurora West Allis Medical Center | West Allis Wisconsin, United States, 53227Marshfield Medical Center - Weston | Weston Wisconsin, United States, 54476Memorial Hospital of Laramie County | Cheyenne Wyoming, United States, 82001Billings Clinic-Cody | Cody Wyoming, United States, 82414Welch Cancer Center | Sheridan Wyoming, United States, 82801
Investigators
Principal Investigator: Lova Sun, ECOG-ACRIN Cancer Research Group